between these features as well as subgroups of patients who may differ in response to therapy.

**Methods** 143 SLE patients were evaluated for clinical phenotype using BILAG-2004, autoantibodies using radioimmunoprecipitation (IP, University of Bath), two interferon scores (IFN-Score-A and IFN-Score-B), flow cytometry for major circulating immune cell subsets, as well as the surface protein expression of tetherin on each subset, a cell-specific assay for IFN response.

Unsupervised hierarchical clustering was used to define autoantibody subgroups. IFN scores (reflected dCT) were compared between the groups using multivariate models. Other variables were compared using Kruskal-Wallis test with pairwise comparisons.

**Results** Using IP, 141 patients could be divided into five subgroups: U1RNP/Sm+only (n=23), Ro60 +only (n=8), U1RNP/Sm+Ro60+ (n=6), Ro60 +Ro52+La+ (n=11), Ro52 + (n=16) and other ANA (n=77).

Antibody subgroups was strongly associated with IFN-Score-A (F=4.39, p=0.001). Expression was lowest for other ANA, intermediate for single antibody groups, and highest with multiple positive antibodies. Multivariate linear regression, including interaction terms between antibody types, revealed that Ro60 and U1RNP/Sm were the independent predictors of IFN-Score-A level (p=0.051 and 0.009 respectively). There was no association between autoantibody status and IFN-Score-B (F=0.973, p=0.438).

In flow cytometry, the U1RNP/Sm group was notable for significantly lower numbers of CD4-T-cells and memory-B-cells. Memory-B-cells were also lower in antibody-positive groups compared to other ANA. Tetherin expression was increased in antibody positive groups, but to a similar extent on most cell subsets. Memory B cell tetherin was significantly higher in the groups with multiple positive antibodies.

U1RNP/Sm+ was associated with renal involvement (p=0.004). Mucocutaneous involvement was greater in the Ro60 +Ro52+La+ group (p=0.037).

**Conclusions** This cohort revealed relationships between immune features. U1RNP/Sm antibody was notable for defining a group of patients with a cluster of immune abnormalities, including the greatest elevation of IFN activity, greater abnormalities on flow cytometry and clinical renal involvement. This was independent to the IFN-Score-B high status that predicts better clinical response to rituximab (presented elsewhere at this conference). Future work in MASTERPLANS will investigate the significance of these subgroups for response to therapy.

**Funding Source(s):** Medical Research Council, National Institute for Health Research

---

**Abstract 295**

**Noninvasive Assessment of Experimental Glomerulonephritis Using Fluorescence Molecular Tomography**


1Washington University School of Medicine; 2University of Cologne; 3St. Jude’s Children’s Research Hospital

**Background** The gold standard for diagnosing lupus nephritis is the renal biopsy. While it has several significant benefits, this procedure is not without risk (i.e. bleeding) and only interrogates a minute portion of the renal parenchyma. Recently, near-infrared fluorescent (NIRF) probes have been developed that can detect pathologic features of kidney disease.

**Abstract 294 Table 1 Multivariate analysis of antibody status and IFN Score A**

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Ab-Negative Score-A Mean(SD)</th>
<th>Ab-Positive Score-A Mean(SD)</th>
<th>Univariate OR (95% CI)</th>
<th>P</th>
<th>Multivariable OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>U1RNP/Sm</td>
<td>3.59 (2.89)</td>
<td>1.46 (1.53)</td>
<td>-2.4 (-2.7,-0.34)</td>
<td>0.012</td>
<td>-2.7 (-2.7,-0.34)</td>
<td>0.009</td>
</tr>
<tr>
<td>Ro60</td>
<td>3.75 (2.82)</td>
<td>1.83 (1.72)</td>
<td>-3.1 (-3.0,-1.83)</td>
<td>0.001</td>
<td>-2.0 (-2.7, 0.0)</td>
<td>0.051</td>
</tr>
<tr>
<td>La</td>
<td>3.39 (2.72)</td>
<td>1.51 (1.99)</td>
<td>-2.0 (-3.7,-1.4)</td>
<td>0.046</td>
<td>-0.35 (-2.7, 1.9)</td>
<td>0.73</td>
</tr>
<tr>
<td>Ro52</td>
<td>3.52 (2.80)</td>
<td>1.95 (1.53)</td>
<td>-2.1 (-2.9,-0.22)</td>
<td>0.023</td>
<td>-0.86 (-2.4, 0.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>U1RNP*Ro60</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td>0.05 (-2.1,2.21)</td>
<td>0.67</td>
</tr>
<tr>
<td>Ro60*Ro52</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td>0.27 (-1.3,5.68)</td>
<td>0.21</td>
</tr>
<tr>
<td>Ro52*La</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td>-0.41 (-10.5,1.26)</td>
<td>0.12</td>
</tr>
</tbody>
</table>

*Note these are untransformed dCT values, so numerically higher values represent lower gene expression

**Abstract 295 Figure 1** Noninvasive detection of cathepsin B activation in experimental glomerulonephritis
utilized to image protein activity noninvasively in animals and humans. We hypothesized that specific inflammatory processes observed in nephritis can be noninvasively detected and monitored using NIRF-based optical imaging approaches. Using a probe that becomes fluorescent in the presence of the protease cathepsin B (CatB), we tested the ability of using NIR optical imaging to assess renal inflammation as a noninvasive marker for early-stage glomerulonephritis (GN).

**Methods** Experimental GN was induced in 129 mice by nephrotoxic serum (NTS) delivered intravenously. Proteinuria was quantified using albumin ELISA and chromogenic creatinine assay. NIR optical imaging of anesthetized mice was performed following intravenous administration of a cleavable sensor for CatB and fluorescence intensity of kidney regions quantified using fluorescence molecular tomography (FMT).

**Results** In NTS-treated mice, a strong fluorescence signal from the CatB-activatable probe was observed as early as day 1, which associated with the onset of proteinuria (figure 1). This signal could be detected for at least 10 days. In contrast, control mice were devoid of any CatB signal. To assess the specificity of CatB signal to GN, we examined CD2AP KO mice that develop nephrotic syndrome in the absence of inflammation. CD2AP KO had no CatB signal despite ongoing nephrosis.

**Conclusions** Induction of GN by NTS was specifically detected noninvasively using a CatB-activatable probe and NIR optical imaging. These data establish the proof-of-principle that novel noninvasive tomographic approaches may represent a translatable approach to establishing early stages of GN. We believe that this approach can be expanded to other experimental imaging approaches, such as photoacoustics, as a novel method for detecting lupus nephritis in humans.

**Funding Source(s):** Department of Defense Discovery Award #W81XWH-17-1-0128 (PI: Kim)

Representative images of a control mouse and a mouse treated with nephrotoxic serum to induce glomerulonephritis (NTS). A strong fluorescence signal induced by cathepsin B is observed in NTS-treated mice only.

---

**ACTIVATED STRESS RESPONSE GENES AND PERTURBATION OF REGULATORY PATHWAYS IN ANTINUCLEAR ANTIBODY POSITIVE INDIVIDUALS AND SLE PATIENTS VARY BY CELL TYPE AND RACE IN SINGLE-CELL TRANSCRIPTOMIC ANALYSES**

Miles Smith*, Samantha Slight-Webb, Susan Macowana, Eliza Chakravarty, Cristina Antiers, Joan T Merrill, Judith A James, Joel Guthridge. Oklahoma Medical Research Foundation

**Background** A universal hallmark of systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While their cognate antigens and ANA levels can associate with SLE subphenotypes, many individuals develop ANAs years prior to autoimmune disease manifestations or never develop any clinical symptoms. At present, the mechanisms governing the transition from autoantibody production to disease onset remain unknown.

**Methods** To ascertain differences in immune cell populations and their transcriptional state, we performed scRNA-seq on peripheral blood mononuclear cells from 30 patients, including African and European American individuals with lupus-associated autoantibodies (n=10), SLE patients (n=10), and ANA-healthy controls (n=10). Transcriptomes were analyzed using canonical correlation analysis, the results of which were used by a smart local moving algorithm to identify cell population clusters and by Uniform Manifold Approximation and Projection for visualization. Differential expression of genes was assessed using Model-based Analysis of Single Cell Transcriptomics.

**Results** Distinct cell populations could be identified for each disease classification. EA ANA+individuals showed a decrease in the number of naïve B cells relative to SLE and healthy individuals; in contrast, AA ANA+individuals had higher numbers of centrocytes. Additionally, AA SLE patients demonstrated an enrichment of plasma cells relative to both ANA+ and healthy individuals while FCRL5, a marker of dysfunctional B cells, was increased only in SLE memory B cells. Overall, AA ANA+cell populations showed an upregulation in a number of heat shock genes in ANA+ (HSPA6, HSPA1A, DNAJB1). Multipotent progenitor (MPP) cells from SLE patients of both ethnicities were marked by upregulation of housekeeping genes (GAPDH, PGK1) while anti-inflammatory NFKB1A was increased in EA MPPs. Comparison of a manually curated list of regulatory factors demonstrated dysregulation of several genes, including upregulation of TGFB across all AA ANA+cell clusters and an increase in CD46 in EA ANA+clusters. Similarly, gene set enrichment analysis of differentially regulated genes indicated activation of stress response pathways in AA and EA ANA+individuals.

**Conclusions** These data indicate that substantial transcriptional and cell population differences exist among immune cells from ANA+, SLE, and healthy individuals, including an activated stress response and enhanced immune regulation in the cells from ANA+individuals. Our results suggest that cells from ANA+individuals may be regulating reactions to stimulation, and exhaustion of that response may allow for transition to SLE.

**Funding Source(s):** NIH U54GM104938, U01AI101934, U19AI082714, and P30AR053483.